Related Experiment Videos
[Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia]
1II Kliniki Psychiatrycznej Katedry Psychiatrii AM w Łodzi.
Psychiatria Polska
|April 28, 2001
Summary
Obsessive-compulsive disorder (OCD) affects 13% of adolescent schizophrenia patients. Atypical antipsychotics like clozapine and risperidone may be linked to new-onset OCD symptoms in schizophrenia.
Area of Science:
- Psychiatry
- Neuroscience
- Clinical Psychology
Background:
- Schizophrenia is a severe mental disorder.
- Obsessive-compulsive disorder (OCD) can co-occur with schizophrenia.
- The relationship between antipsychotic medication and OCD onset in schizophrenia requires further investigation.
Purpose of the Study:
- To determine the prevalence of OCD in adolescent schizophrenia patients.
- To investigate the timing of OCD onset in relation to schizophrenia diagnosis and neuroleptic treatment.
- To explore potential links between specific atypical antipsychotics and OCD development.
Main Methods:
- Study included 200 adolescent inpatients and outpatients diagnosed with schizophrenia.
- Diagnostic interviews using SCID-P (DSM-III-R, DSM-IV) were conducted.
- Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and a custom questionnaire assessed OCD and onset details.
Main Results:
- OCD was diagnosed in 13% of adolescent schizophrenia patients.
- OCD onset occurred before schizophrenia (2%), with schizophrenia (4.5%), or during atypical neuroleptic treatment (6%).
- Patients on clozapine (14.3%) and risperidone (12.5%) showed higher OCD prevalence during treatment compared to olanzapine (5.9%).
- No OCD was observed with prior classical neuroleptic use.
- No statistically significant differences were found between atypical antipsychotics regarding OCD onset.
Conclusions:
- A significant portion of adolescent schizophrenia patients exhibit OCD.
- Atypical antipsychotics, particularly clozapine and risperidone, may be associated with the emergence of OCD symptoms.
- Further research is needed to understand the mechanisms, possibly involving serotonergic pathways or shared symptomatology.